Peptides are short chains of amino acids, smaller than proteins, that occur naturally in the body and in food. They act as precision chemical messengers, regulating critical processes such as metabolism, growth, immunity, and tissue repair. However, synthetic peptides created in labs and promoted on social media for weight loss, muscle growth, tanning, and anti-ageing are raising concerns among health regulators.
What Are Peptides and How Do They Work?
Peptides are water-soluble and cannot pass directly through cell membranes. Instead, they bind to receptors on the surface of target cells, triggering cascades of events inside. Key categories include peptide hormones (e.g., human growth hormone), neuropeptides (e.g., endorphins), growth factors (e.g., IGF-1), and immune modulators (e.g., thymosin alpha-1). Some peptides, like insulin and GLP-1 receptor agonists, are legitimate medicines used for diabetes and weight loss.
The Rise of Enhancement Peptides
The recent boom in peptide use is driven by products promoted online for “optimisation” – weight loss, muscle growth, injury recovery, tanning, anti-ageing, and libido. Most users inject peptides subcutaneously with insulin-style needles, though nasal sprays, tablets, and creams are also available. Social media influencers normalise these substances by injecting them online and sharing referral links, blurring the line between treating illness and enhancing a healthy body.
Regulation and Legal Status in Australia
In Australia, peptide products for therapeutic use are regulated as therapeutic goods by the Therapeutic Goods Administration (TGA). Many products advertised or sold online, such as BPC-157, retatrutide, GHK-Cu, TB-500, and CJC-1295, are not TGA-approved, meaning they haven’t been assessed for safety, quality, or effectiveness. Importing or supplying them for human use without authorisation is illegal. However, people still access these substances via online vendors, often labelled as “research chemicals” – a loophole used in the US but not applicable in Australia.
Risks and Unknowns
The biggest risk is not always the peptide itself. Laboratory testing by researchers found that retatrutide doses were almost double the labelled amount. Products may contain impurities, contaminants, or entirely different substances. Even correctly labelled peptides carry unknown risks due to lack of human trial data. Injecting introduces risks of infection, abscesses, scarring, and blood-borne viruses if equipment is shared. Many users do not disclose their use to health services, missing out on harm-reduction advice.
What Needs to Be Done
As peptide use grows, Australia needs coordinated surveillance to monitor emerging products and harms, stricter enforcement of advertising rules for unapproved therapeutic goods, and accountability for platforms hosting referral-link selling. Clinicians require better education to address peptide use in practice, and evidence-based information must reach users through the same online platforms where products are promoted. Research on the wider enhancement ecosystem – including product switching, sourcing information, dosing protocols, and online community norms – is critical. Harm reduction, health education, and online literacy will be essential to prevent avoidable injuries as evidence evolves.
